Global Expansion Strategy of Japan's Pharma Companies*

Notable M&A activity during 2008/2009 has included Eisai Co.'s acquisition of U.S.-based cancer specialist MGI Pharma Inc., Takeda Pharmaceutical Co. acquiring U.S.-based Millennium Pharmaceuticals Inc., Shionogi & Co. purchasing U.S.-based Sciele Pharma Inc., Daiichi Sankyo Co.'s acquisition of India generic manufacturer Ranbaxy Laboratories Ltd., and Dainippon Sumitomo Pharma Co.'s purchase of U.S.-based Sepracor Inc. A Growing Domestic Market In addition to expansion through acquisition strategies, Japanese pharmaceutical manufacturers may realize opportunities closer to home, as the Asia-Pacific region is a major emerging market for the development of orphan drugs. Many leading Asian countries have a legal framework for the development of novel medicines, and the market for the region is expected to notice significant growth. In fact, Japan's more than $60+ billion pharmaceutical market value is expected to top $100 billion by 2020. Regional growth will be propelled by a strong patent market, as generic drug use is less prevalent in Japan than in the United States and other regions. Plus, Japan is dealing with an aging population and an increase in chronic diseases, which contributes to Japan having the highest number of prescriptions per patient. Get your copy of this report to:

*View statistical data and analytical reviews of the top companies based in the country
*Identify the top therapeutic areas in terms of growth percentage for the region
*Gain insight into the M&A activity and future business strategy of Japanese companies growing their global presence
*Track potential competitive products as Japanese companies look to expand into new markets, and learn how these could affect your company's bottom-line

ORDER NOW